Products
Denintuzumab Mafodotin Biosimilar Antibody-Drug Conjugate (CD19) for Research
Pre-made Denintuzumab Mafodotin benchmark antibody (Whole mAb ADC, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Denintuzumab mafodotin (INN; development codes SGN-19A or SGN-CD19A) is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.[1][2][3][4] It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.[5] This drug was developed by Seattle Genetics.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-800-1mg | 1mg | 4635 |
| GMP-Bios-INN-800-10mg | 10mg | |
| GMP-Bios-INN-800-100mg | 100mg | |
| GMP-Bios-INN-800-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Denintuzumab Mafodotin Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugate |
| INN Name | Denintuzumab Mafodotin |
| Target | CD19 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Seattle genetics, Inc. (Bothell WA USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - CD19
1. Protein B-lymphocyte antigen CD19
2. Gene CD19
3. Organism Homo sapiens (Human)
Function
Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:2463100, PubMed:1373518, PubMed:16672701).
Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2+ stores (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701).
Is not required for early steps during B cell differentiation in the blood marrow (PubMed:9317126).
Required for normal differentiation of B-1 cells (By similarity).
Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:2463100, PubMed:1373518).
Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701).
